spinal muscular atrophy: Spinal muscular atrophy is a disorder of spinal motor neurons characterized clinically by the development of muscle weakness and atrophy.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
307 |
4. Check minimum number of eventsNone |
307 |
5. Include endpointsNone |
307 |
6. Filter based on genotype QC (FinnGen only) |
302 |
Control definitions (FinnGen only)
- Control exclude
- G6_NEUATR
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other and unspecified spinal muscular atrophies
based on the number of shared cases.
Similar with more cases:
- Systemic atrophies primarily affecting the central nervous system
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3434 | 1501 | 1850 |
| Only index persons | 1766 | 795 | 971 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.04 | 0.05 |
| Only index persons | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 60.57 | 61.22 | 59.94 |
| Only index persons | 56.32 | 57.03 | 55.75 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 302 | 118 | 184 |
| Unadjusted period prevalence (%) | 0.07 | 0.04 | 0.08 |
| Median age at first event (years) | 59.98 | 55.49 | 62.86 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 307
- Matched controls
- 3070
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G12.9
ICD-10 Finland
Spinal muscular atrophy, unspecified
+∞
167.5
145
*
G12.8
ICD-10 Finland
Other spinal muscular atrophies and related syndromes
+∞
106.6
96
*
G12.2
ICD-10 Finland
Motor neuron disease
+∞
77.4
71
*
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
11.2
42.4
48
50
N03AE01
ATC
clonazepam; systemic
8.7
40.0
56
77
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.3
34.6
67
130
34899
ICD-8 Finland
Motor neurone disease, Other and unspecified manifestations
+∞
28.6
27
*
G12.1
ICD-10 Finland
Other inherited spinal muscular atrophy
+∞
27.5
26
*
N99
ICPC
Neurological disease other
46.0
27.4
33
8
TAB00
NOMESCO Finland
Lumbar puncture
6.8
24.4
41
68
G72.9
ICD-10 Finland
Myopathy, unspecified
23.5
18.5
26
12
N07XX02
ATC
riluzole; oral
+∞
16.8
16
*
L28
ICPC
Limited function/disability (L)
3.2
16.7
83
319
SPAT1229
SPAT
Assessment of need for aid
4.5
16.4
44
111
J96.1
ICD-10 Finland
Chronic respiratory failure
7.4
15.9
24
35
N28
ICPC
Limited function/disability (N)
14.4
14.5
24
18
Z31.5
ICD-10 Finland
Genetic counselling
5.0
12.9
29
63
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
33.6
12.7
16
5
M03BX01
ATC
baclofen; systemic
10.7
11.7
22
22
G13.0
ICD-10 Finland
Paraneoplastic neuromyopathy and neuropathy
+∞
11.5
11
*
3352A
ICD-9 Finland
Anterior horn cell disease, Motor neuron disease[SCLEROSIS LATERALIS AMYOTROPHICA]
+∞
11.5
11
*
3351X
ICD-9 Finland
Anterior horn cell disease, Spinal muscular atrophy[ATROPHIA MUSCULORUM SPINALIS NUD]
+∞
11.5
11
*
G60.0
ICD-10 Finland
Hereditary motor and sensory neuropathy
45.0
11.0
13
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.9
10.7
33
92
34898
ICD-8 Finland
Motor neurone disease, Alii definiti
+∞
10.5
10
*
G62.8
ICD-10 Finland
Other specified polyneuropathies
15.3
10.1
16
11
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
8.1
10.1
22
29
NXL00
NOMESCO Finland
Biopsy of muscle
41.5
10.0
12
*
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.8
9.9
23
51
R1250
NOMESCO Finland
Evaluation of functional capability
7.4
9.2
21
30
R47.1
ICD-10 Finland
Dysarthria and anarthria
11.2
8.9
16
15
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.4
8.9
23
56
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
51.5
8.7
10
*
G13.2*E03.9
ICD-10 Finland
Systemic atrophy primarily affecting central nervous system in myxoedema
+∞
8.4
8
*
Z50.1
ICD-10 Finland
Other physical therapy
3.7
8.3
27
78
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.6
8.2
54
236
N29
ICPC
Neurological sympt/complt other
8.1
8.0
17
22
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.0
7.9
36
129
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.0
7.7
35
125
G71.08
ICD-10 Finland
Other muscular dystrophy
82.0
7.4
8
*
R13
ICD-10 Finland
Dysphagia
3.0
7.4
35
128
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
7.4
63
309
M62.5
ICD-10 Finland
Muscle wasting and atrophy, not elsewhere classified
30.8
7.2
9
*
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
41.0
6.8
8
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.5
6.7
46
204
N03AX12
ATC
[U] gabapentin; oral
2.2
6.6
61
309
JDB10
NOMESCO Finland
Percutaneous gastrostomy
8.4
6.4
13
16
33098
ICD-8 Finland
Hereditary neuromuscular disorders, Alii definiti
+∞
6.3
6
*
G12.0
ICD-10 Finland
Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
46
157
3.27
11.01
2.4
2.4
—
6.96
—
0
8
16
21
7.97
7.48
1.2
1.0
—
—
—
0
0
17
28
6.36
6.87
1.2
1.0
—
—
—
0
0
10
6
17.15
6.79
1.1
1.2
—
—
—
0
0
13
16
8.43
6.40
1.3
1.0
—
—
—
0
0
10
10
10.29
5.57
1.3
1.0
1.87
1.77
mmol/l
—
10
10
8
5
16.36
5.44
1.3
1.0
—
—
—
0
0
7
7
10.19
4.03
1.1
1.0
—
—
—
0
0
7
7
10.19
4.03
1.1
1.0
—
—
—
0
0
7
8
8.92
3.79
1.0
1.1
—
—
%
—
0
0
15
50
3.10
3.74
2.9
2.2
17.90
15.71
%
—
10
25
13
43
3.11
3.29
1.2
1.4
—
—
—
0
0
202
2303
0.64
3.25
4.9
5.2
2.75
2.65
mmol/l
0.78
178
2108
24
114
2.20
3.03
3.5
3.0
0.68
0.66
%
0.11
24
114
198
2255
0.66
3.00
4.5
4.6
4.66
4.52
mmol/l
1.06
178
2080
7
13
5.48
2.88
3.3
2.0
—
—
—
0
0
6
9
6.77
2.88
1.3
1.2
—
—
—
0
0
6
9
6.77
2.88
1.3
1.0
—
—
—
0
0
24
117
2.14
2.86
3.5
3.1
1.10
1.16
%
0.14
24
117
197
2238
0.67
2.84
4.4
4.6
1.47
1.43
mmol/l
0.48
175
2048
40
639
0.57
2.82
1.6
1.7
1.27
1.34
mmol/l
0.30
33
535
6
10
6.09
2.71
1.3
1.1
—
—
—
0
0
187
2137
0.68
2.67
7.2
6.2
39.99
40.64
mmol/mol
0.48
169
1981
234
2558
0.64
2.65
28.7
22.6
4.43
4.48
e12/l
0.58
229
2473
58
390
1.60
2.51
3.0
3.6
0.83
0.83
mmol/l
0.02
53
367
33
190
1.83
2.49
3.4
3.6
4.40
4.31
kpa
0.12
33
181
235
2557
0.65
2.42
28.1
22.7
39.19
40.05
%
1.00
222
2378
5
8
6.33
2.38
1.4
1.0
—
—
—
0
0
5
8
6.33
2.38
1.4
1.0
—
—
—
0
0
5
8
6.33
2.38
1.4
1.0
—
—
—
0
0
114
898
1.43
2.30
5.1
4.0
—
—
—
0
0
192
2160
0.70
2.26
4.2
4.2
1.36
1.27
mmol/l
0.86
172
1961
201
2243
0.70
2.25
5.0
4.8
5.88
6.02
mmol/l
1.30
183
2043
62
849
0.66
2.21
4.7
4.6
23.81
21.64
%
0.60
41
430
8
24
3.39
2.19
1.3
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
10
5.06
2.08
1.4
1.0
—
—
—
0
0
12
50
2.46
2.05
1.2
1.1
—
—
—
0
0
36
226
1.67
2.05
3.7
4.6
2.98
1.77
mmol/l
1.23
31
181
36
227
1.66
2.02
3.8
4.6
6.00
5.75
kpa
0.84
36
219
21
112
1.94
2.02
1.0
1.2
63.92
129.37
iu/ml
—
5
44
136
1127
1.37
1.98
6.9
5.1
0.00
0.00
estimate
-0.00
30
226
28
166
1.76
1.95
1.6
1.6
—
—
—
0
0
5
11
4.60
1.95
1.0
3.5
29.40
28.73
umol/l
—
5
11
9
33
2.78
1.94
1.8
1.9
12.33
16.86
ug/l
—
9
33
143
1198
1.36
1.93
8.3
7.2
1.21
1.21
mmol/l
0.16
116
1010
113
912
1.38
1.92
2.3
2.2
80.40
77.56
nmol/l
0.51
102
807
88
682
1.41
1.90
4.9
3.4
0.29
0.46
e6/l
0.70
78
515
71
532
1.44
1.85
1.8
1.8
498.19
22045892.11
pmol/l
0.79
63
440
137
1146
1.35
1.84
5.0
3.8
0.00
0.00
estimate
-0.00
28
212
109
884
1.36
1.78
5.2
3.4
—
—
—
0
0
12
55
2.23
1.69
1.6
1.2
—
—
—
0
0
57
417
1.45
1.68
3.7
3.0
0.95
1.08
e6/l
0.15
44
247
134
1130
1.33
1.67
4.9
3.8
0.00
0.00
estimate
-0.00
35
246
198
2174
0.75
1.60
18.7
14.5
86.87
78.06
ml/min/173m2
4.57
178
1807
8
169
0.46
1.52
1.8
1.7
—
—
—
0
0
0
45
0.00
1.51
0.0
1.3
—
—
—
0
0
6
22
2.76
1.44
4.0
3.5
26.65
60.62
u/ml
—
6
22
60
771
0.72
1.44
4.7
3.8
2.72
8.49
mg/mmol
3.90
41
497
6
23
2.64
1.37
1.0
1.1
—
—
—
0
0
5
17
2.97
1.36
1.0
1.9
84.20
80.94
umol/l
—
5
17
6
24
2.53
1.31
1.0
1.2
—
—
—
0
0
5
18
2.81
1.29
1.0
1.1
—
—
—
0
0
5
18
2.81
1.29
1.0
1.1
—
—
—
0
0
8
159
0.49
1.28
1.0
1.8
—
—
—
0
0
6
25
2.43
1.25
1.0
1.8
—
—
—
0
0
47
612
0.73
1.22
3.0
3.1
0.93
0.78
ug/l
0.90
33
409
136
1187
1.26
1.21
15.1
15.0
1.21
1.28
inr
0.51
38
335
27
183
1.52
1.18
4.0
2.6
99.92
61.63
ml/min/173m2
0.39
13
78
5
20
2.52
1.15
1.4
1.3
—
—
—
0
0
159
1419
1.25
1.15
5.4
5.1
6.61
6.78
mmol/l
0.49
149
1320
7
32
2.21
1.08
1.0
1.2
—
—
—
0
0
7
33
2.15
1.06
2.9
4.4
—
—
—
0
0
60
481
1.31
1.04
1.8
1.7
1249.58
1197.88
nmol/l
0.16
53
360
64
518
1.30
1.03
5.0
4.1
1.02
1.02
kg/l
0.06
15
66
12
69
1.77
0.98
1.2
1.2
—
—
—
0
0
92
1063
0.81
0.94
5.4
5.3
26.55
2.89
ug/l
0.93
87
934
5
104
0.47
0.90
1.0
1.0
—
—
—
0
0
21
298
0.68
0.90
8.3
7.8
—
—
—
0
0
118
1319
0.83
0.85
2.4
2.8
—
—
—
0
0
49
396
1.28
0.81
4.6
3.3
1.89
1.65
e6/l
0.13
36
229
0
25
0.00
0.79
0.0
1.1
—
—
—
0
0
140
1269
1.19
0.78
5.5
6.6
11.75
11.85
umol/l
0.02
132
1196
7
40
1.77
0.71
2.4
3.0
108.71
105.07
mmol/l
—
7
40
74
638
1.21
0.70
5.4
4.0
0.00
0.00
estimate
-0.00
30
215
16
111
1.47
0.67
1.9
2.3
—
—
—
0
0
39
315
1.27
0.66
6.0
7.1
102.56
104.19
mmol/l
1.10
39
315
44
361
1.26
0.66
1.3
1.3
1.03
13.03
u/ml
2.33
19
144
10
62
1.63
0.66
1.5
1.3
—
—
—
0
0
12
176
0.67
0.64
1.3
2.0
—
—
—
0
0
223
2330
0.84
0.64
20.2
15.5
26.03
24.42
mg/l
0.25
194
1877
21
156
1.37
0.63
1.8
1.4
—
—
—
0
0
5
30
1.68
0.61
1.4
1.3
—
—
—
0
0
179
1678
1.16
0.61
4.2
3.7
15.16
14.79
pmol/l
1.22
169
1491
8
51
1.58
0.61
1.1
1.6
—
—
—
0
0
11
72
1.55
0.60
1.4
2.0
—
—
—
0
0
8
54
1.49
0.57
1.3
1.4
—
—
—
0
0
24
306
0.77
0.57
4.8
4.7
30.83
31.86
%
0.18
18
208
32
258
1.27
0.56
5.2
3.6
—
—
—
0
0
8
55
1.47
0.56
1.1
1.7
—
—
—
0
0
6
38
1.59
0.54
1.0
1.3
—
—
—
0
0
108
983
1.15
0.54
2.2
2.0
92.75
94.44
pmol/l
0.12
60
519
117
1076
1.14
0.50
2.8
2.7
—
—
—
0
0
53
459
1.19
0.49
2.3
3.1
2.44
2.45
mmol/l
0.06
48
396
43
365
1.21
0.49
1.4
1.3
28.81
36.65
iu/ml
0.25
11
117
48
412
1.20
0.49
2.1
1.9
—
—
—
0
0
7
46
1.53
0.48
1.4
1.4
—
—
—
0
0
7
46
1.53
0.48
1.4
1.4
—
—
—
0
0
7
46
1.53
0.48
1.1
1.6
—
—
—
0
0
7
48
1.47
0.47
1.1
1.4
—
—
—
0
0
7
51
1.38
0.44
1.1
1.3
—
—
—
0
0
5
32
1.57
0.42
1.4
1.3
—
—
—
0
0
5
32
1.57
0.42
1.4
1.3
—
—
—
0
0
5
32
1.57
0.42
1.4
1.3
—
—
—
0
0
5
32
1.57
0.42
1.4
1.3
—
—
—
0
0
5
33
1.52
0.41
1.4
1.3
—
—
—
0
0
5
33
1.52
0.41
1.4
1.7
—
—
—
0
0
0
17
0.00
0.41
0.0
1.7
—
—
—
0
0
0
17
0.00
0.41
0.0
1.7
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
10
71
1.42
0.39
1.1
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
71
645
1.13
0.37
3.6
2.8
10456.59
8506.02
umol/l
0.10
63
548
6
41
1.47
0.36
8.5
2.9
62.83
58.59
%
—
6
41
107
999
1.11
0.35
4.0
3.9
89.89
43.85
ng/l
0.56
85
735
56
505
1.13
0.33
1.8
1.8
1.83
1.44
mg/l
0.20
45
399
33
287
1.17
0.31
1.9
1.9
—
—
—
0
0
53
478
1.13
0.31
1.2
1.2
0.79
0.92
u/ml
0.33
16
123
12
93
1.30
0.30
2.3
1.6
—
—
—
0
0
70
644
1.11
0.30
2.2
2.1
3.22
3.06
mg/l
0.17
59
560
144
1374
1.09
0.29
9.3
9.5
4.31
4.14
e9/l
0.30
135
1213
14
112
1.26
0.29
8.7
9.1
1.53
1.54
%
0.02
14
107
67
617
1.11
0.28
1.7
1.6
17.84
20.36
nmol/l
1.00
61
520
8
64
1.26
0.27
1.3
1.5
—
—
—
0
0
8
65
1.24
0.27
1.0
1.3
—
—
—
0
0
12
96
1.26
0.25
2.4
1.8
—
—
—
0
0
115
1097
1.08
0.23
8.1
6.3
1.20
1.21
mmol/l
0.73
107
986
5
39
1.29
0.23
2.6
3.1
82.80
33.73
u/ml
—
5
39
7
92
0.76
0.23
1.4
3.3
—
—
—
0
0
5
40
1.25
0.22
1.6
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
216.20
—
0
10
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
5
43
1.17
0.21
1.2
1.7
—
—
—
0
0
5
43
1.17
0.21
1.2
1.7
—
—
—
0
0
32
288
1.12
0.21
2.0
2.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
32
289
1.12
0.20
8.4
8.8
3.04
1.23
mmol/l
1.79
24
227
6
52
1.16
0.19
1.2
1.4
—
—
—
0
0
7
60
1.17
0.18
1.7
1.6
—
—
—
0
0
7
61
1.15
0.17
1.7
1.6
—
—
—
0
0
206
2094
0.95
0.13
5.2
4.5
1.85
1.96
mu/l
0.69
193
1881
9
110
0.81
0.13
1.6
1.3
—
—
—
0
0
29
269
1.09
0.12
1.5
1.4
—
—
—
0
0
53
554
0.95
0.10
2.4
2.4
—
—
—
0
0
5
45
1.11
0.10
1.8
1.5
—
—
—
0
0
14
151
0.92
0.05
2.4
1.7
—
—
—
0
0
39
400
0.97
0.03
2.1
2.0
29.59
29.24
s
0.24
39
389
97
981
0.98
0.02
3.0
2.7
291.57
144.25
ug/l
0.96
89
899
79
780
1.02
0.02
3.0
3.2
1734.69
1463.43
ng/l
0.19
67
667
46
469
0.98
0.02
3.0
3.7
63.17
259.29
ng/l
1.47
35
376
152
1510
1.01
0.02
3.2
3.1
50.58
51.19
u/l
0.02
139
1404
12
127
0.94
0.01
1.3
1.7
1.76
1.48
g/l
0.48
12
113
32
322
0.99
0.00
1.2
1.4
—
—
—
0
0
176
1759
1.00
0.00
5.0
4.0
13.29
13.07
mm/h
0.06
161
1602
13
125
1.04
0.00
1.1
1.2
759.08
166.80
u/ml
0.91
13
110
29
294
0.98
0.00
2.1
3.2
5.09
8.60
umol/l
2.35
23
262
0
9
0.00
0.00
0.0
1.2
—
143.56
—
0
9
0
9
0.00
0.00
0.0
1.2
—
53.00
—
0
9
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
98.80
—
0
5
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
6
69
0.87
-0.00
1.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
6.58
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
69
0.87
-0.00
1.7
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
6
69
0.87
-0.00
1.7
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_SPINAMUSCOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_SPINAMUSCOTH | 5.729 [4.42, 7.42] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.129 |
During the follow-up period (1.1.1998 — 31.12.2019), 309 out of 670 females with G6_SPINAMUSCOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_SPINAMUSCOTH | 3.826 [3.06, 4.79] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 340 out of 805 males with G6_SPINAMUSCOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_SPINAMUSCOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.497% | 0.723% |
| 5 | 3.225% | 3.906% |
| 10 | 6.97% | 10.02% |
| 15 | 14.373% | 18.355% |
| 20 | 23.91% | 30.396% |
Relationships between endpoints
↥Index endpoint: G6_SPINAMUSCOTH – Other and unspecified spinal muscular atrophies
GWS hits: 9
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data